Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.03 USD | -8.56% | -13.59% | -40.17% |
Financials (USD)
Sales 2024 * | 307K | Sales 2025 * | 3.11M | Capitalization | 818M |
---|---|---|---|---|---|
Net income 2024 * | -266M | Net income 2025 * | -293M | EV / Sales 2024 * | 1,302 x |
Net cash position 2024 * | 418M | Net cash position 2025 * | 587M | EV / Sales 2025 * | 74.3 x |
P/E ratio 2024 * |
-2.96
x | P/E ratio 2025 * |
-3
x | Employees | 94 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.57% |
Latest transcript on Viridian Therapeutics, Inc.
1 day | -8.56% | ||
1 week | -13.59% | ||
Current month | -25.59% | ||
1 month | -27.65% | ||
3 months | -30.62% | ||
6 months | +16.34% | ||
Current year | -40.17% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 23-10-29 | |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 23-04-30 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 18-01-02 |
Tomas Kiselak
CHM | Chairman | 38 | 20-10-27 |
Chief Executive Officer | 53 | 23-10-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.06% | 237 M€ | +1.49% | - | |
0.02% | 2 M€ | -.--% | ||
0.01% | 773 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 13.03 | -8.56% | 771,185 |
24-04-23 | 14.25 | -0.35% | 538,427 |
24-04-22 | 14.3 | -2.05% | 812,430 |
24-04-19 | 14.6 | -3.69% | 1,489,694 |
24-04-18 | 15.16 | +0.53% | 580,684 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.17% | 818M | |
+4.09% | 43.84B | |
+47.81% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- VRDN Stock